Bibliography
- Shin JM, Sachs G. Differences in binding properties of two proton pump inhibitors on the gastric H+,K+-ATPase in vivo. Biochem Pharmacol 2004;68:2117-27
- Bell NJ, Burget D, Howden CW, et al. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992;51(Suppl 1):59-67
- Hunt RH. The relationship between the control of pH and healing and symptom relief in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995;9(Suppl 1):3-7
- Sachs G, Shin JM, Howden CW. Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther 2006;23(Suppl 2):2-8
- Orr WC. Night-time gastro-oesophageal reflux disease: prevalence, hazards, and management. Eur J Gastroenterol Hepatol 2005;17:113-20
- Kahrilas PJ, Dent J, Lauritsen K, et al. A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. Clin Gastroenterol Hepatol 2007;5:1385-91
- Dent J, Kahrilas PJ, Hatlebakk J, et al. A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease. Am J Gastroenterol 2008;103:20-6
- Simon WA, Herrmann M, Klein T, et al. Soraprazan: setting new standards in inhibition of gastric acid secretion. J Pharmacol Exp Ther 2007;321:866-74
- Abelo A, Andersson M, Holmberg AA, Karlsson MO. Application of a combined effect compartment and binding model for gastric acid inhibition of AR-HO47108: a potassium competitive acid blocker, and its active metabolite AR-HO47116 in the dog. Eur J Pharm Sci 2006;29:91-101
- Huber R, Hartmann M, Bliesath H, et al. Pharmacokinetics of pantoprazole in man. Int J Clin Pharmacol Ther 1996;34:S7-16
- Radhofer-Welte S. Pharmacokinetics and metabolism of the proton pump inhibitor pantoprazole in man. Drugs Today (Barc) 1999;35:765-72
- Gladziwa U, Koltz U. Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure. Clin Pharmacokinet 1994;27:393-408
- Kliem V, Bahlmann J, Hartmann M, et al. Pharmacokinetics of pantoprazole in patients with end-stage renal failure. Nephrol Dial Transplant 1998;13:1189-93
- Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 1996;31:9-28
- Ferron GM, Preston RA, Noveck RJ, et al. Pharmacokinetics of pantoprazole in patients with moderate and severe hepatic dysfunction. Clin Ther 2001;23:1180-92
- Klotz U. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int J Clin Pharmacol Ther 2006;44:297-302
- Leontiadis GI, Sharma VK, Howden CW. Systematic review and meta-analysis: enhanced efficacy of proton-pump inhibitor therapy for peptic ulcer bleeding in Asia – a post hoc analysis from the Cochrane Collaboration. Aliment Pharmacol Ther 2005;21:1055-61
- Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002;41:913-58
- Hunfeld NG, Mathot RA, Touw DJ, et al. Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians. Br J Clin Pharmacol 2008; in Press
- Pue MA, Laroche J, Meineke I, de Mey C. Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects. Eur J Clin Pharmacol 1993;44:575-8
- Plante L, Ferron GM, Unruh M, Mayer PR. Excretion of pantoprazole in human breast. J Reprod Med 2004;49:825-27
- Simon B, Muller P, Bliesath H, et al. Single intravenous administration of the H+, K(+)-ATPase inhibitor BY 1023/SK&F 96022: inhibition of pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man. Aliment Pharmacol Ther 1990;4:239-45
- Simon B, Muller P, Hartmann M, et al. Pentagastrin-stimulated gastric acid secretion and pharmacokinetics following single and repeated intravenous administration of the gastric H+, K(+)-ATPase-inhibitor pantoprazole (BY1023/SK&F96022) in healthy volunteers. Z Gastroenterol 1990;28:443-7
- Simon B, Muller P, Marinis E, et al. Effect of repeated oral administration of BY 1023/SK&F 96022, a new substituted benzimidazole derivative, on pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man. Aliment Pharmacol Ther 1990;4:373-9
- Tanaka M, Yamazaki H, Ryokawa Y, et al. Pharmacokinetics and tolerance of pantoprazole, a proton pump inhibitor after single and multiple oral doses in healthy Japanese volunteers. Int J Clin Pharmacol Ther 1996;34:415-9
- Schulz HU, Hartmann M, Steinijans VW, et al. Lack of influence of pantoprazole on the disposition kinetics of theophylline in man. Int J Clin Pharmacol Ther Toxicol 1991;29:369-75
- De Mey C, Meineke I, Steinijans VW, et al. Pantoprazole lacks interaction with antipyrine in man, either by inhibition or induction. Int J Clin Pharmacol Ther 1994;32:98-106
- Koch HJ, Hartmann M, Bliesath H, et al. Pantoprazole has no influence on steady state pharmacokinetics and pharmacodynamics of metoprolol in healthy volunteers. Int J Clin Pharmacol Ther 1996;34:420-3
- Muller P, Simon B, Khalil H, et al. Dose-range finding study with the proton pump inhibitor pantoprazole in acute duodenal ulcer patients. Z Gastroenterol 1992;30:771-5
- Locke GR 3rd, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997;112:1448-56
- Bommelaer G. Gastroesophageal reflux in the adult. Definition, epidemiology, natural history. Gastroenterol Clin Biol 1999;23:S3-9
- Colin-Jones DG. The role and limitations of H2-receptor antagonists in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995;9(Suppl 1):9-14
- Monnikes H, Pfaffenberger B, Gatz G, et al. Novel measurement of rapid treatment success with ReQuest: first and sustained symptom relief as outcome parameters in patients with endoscopy-negative GERD receiving 20 mg pantoprazole or 20 mg esomeprazole. Digestion 2007;75(Suppl 1):62-8
- Bardhan KD, Stanghellini V, Armstrong D, et al. International validation of ReQuest in patients with endoscopy-negative gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2004;20:891-8
- Ducrotte P, Zerbib F. ReQuest: a new questionnaire for the simultaneous evaluation of symptoms and well-being in patients with gastro-oesophageal reflux. Digestion 2007;75(Suppl 1):79-86
- Scholten T, Teutsch I, Bohuschke M, Gatz G. Pantoprazole on-demand effectively treats symptoms in patients with gastro-oesophageal reflux disease. Clin Drug Investig 2007;27:287-96
- Scholten T, Dekkers CP, Schutze K, et al. On-demand therapy with pantoprazole 20 mg as effective long-term management of reflux disease in patients with mild GERD: the ORION trial. Digestion 2005;72:76-85
- Caro JJ, Salas M, Ward A. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. Clin Ther 2001;23:998-1017
- Bardhan KD. Pantoprazole: a new proton pump inhibitor in the management of upper gastrointestinal disease. Drugs Today (Barc) 1999;35:773-808
- Bardhan KD. Triple therapy as a cure for Helicobacter pylori infection. Eur J Gastroenterol Hepatol 1996;8(Suppl 1):S27-30
- Labenz J, Tillenburg B, Weismuller J, et al. Efficacy and tolerability of a one-week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin for cure of Helicobacter pylori infection in patients with duodenal ulcer. Aliment Pharmacol Ther 1997;11:95-100
- Adamek RJ, Bethke TD. Cure of Helicobacter pylori infection and healing of duodenal ulcer: comparison of pantoprazole-based one-week modified triple therapy versus two-week dual therapy. The International Pantoprazole HP Study Group. Am J Gastroenterol 1998;93:1919-24
- Dajani AI, Awad S, Ukabam S, et al. One-week triple regime therapy consisting of pantoprazole, amoxicillin and clarithromycin for cure of Helicobacter pylori-associated upper gastrointestinal diseases. Digestion 1999;60:298-304
- Choi HS, Park DI, Hwang SJ, et al. Double-dose, new-generation proton pump inhibitors do not improve Helicobacter pylori eradication rate. Helicobacter 2007;12:638-42
- Aydin A, Onder G, Akarca U, et al. Comparison of 1- and 2-week pantoprazole-based triple therapies in clarithromycin-sensitive and resistant cases. Eur J Intern Med 2007;18:496-500
- Zagari RM, Bianchi-Porro G, Fiocca R, et al. Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study. Gut 2007;56:475-9
- Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-81
- Gonzalez Carro P, Perez Roldan F, De Pedro Esteban A, et al. Efficacy of rifabutin-based triple therapy in Helicobacter pylori infected patients after two standard treatments. J Gastroenterol Hepatol 2007;22:60-3
- Gisbert JP, Khorrami S, Calvet X, Pajares JM. Pantoprazole based therapies in Helicobacter pylori eradication: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2004;16:89-99
- Fornai M, Natale G, Colucci R, et al. Mechanisms of protection by pantoprazole against NSAID-induced gastric mucosal damage. Naunyn Schmiedebergs Arch Pharmacol 2005;372:79-87
- Rahme E, Bardou M, Dasgupta K, et al. Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study. Rheumatology (Oxford) 2007;46:265-72
- Rostom A, Wells G, Tugwell P, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2000:CD002296
- Regula J, Butruk E, Dekkers CP, et al. Prevention of NSAID-associated gastrointestinal lesions: a comparison study pantoprazole versus omeprazole. Am J Gastroenterol 2006;101:1747-55
- van Leen MW, van der Eijk I, Schols JM. Prevention of NSAID gastropathy in elderly patients. An observational study in general practice and nursing homes. Age Ageing 2007;36:414-8
- Bardou M, Toubouti Y, Benhaberou-Brun D, et al. Meta-analysis: proton-pump inhibition in high-risk patients with acute peptic ulcer bleeding. Aliment Pharmacol Ther 2005;21:677-86
- Leontiadis GI, Sharma VK, Howden CW. Proton pump inhibitor therapy for peptic ulcer bleeding: Cochrane collaboration meta-analysis of randomized controlled trials. Mayo Clin Proc 2007;82:286-96
- Zargar SA, Javid G, Khan BA, et al. Pantoprazole infusion as adjuvant therapy to endoscopic treatment in patients with peptic ulcer bleeding: prospective randomized controlled trial. J Gastroenterol Hepatol 2006;21:716-21
- Jensen DM, Pace SC, Soffer E, Comer GM. Continuous infusion of pantoprazole versus ranitidine for prevention of ulcer rebleeding: a US multicenter randomized, double-blind study. Am J Gastroenterol 2006;101:1991-9
- Corazziari E. Definition and epidemiology of functional gastrointestinal disorders. Best Pract Res Clin Gastroenterol 2004;18:613-31
- Locke GR 3rd. Prevalence, incidence and natural history of dyspepsia and functional dyspepsia. Baillieres Clin Gastroenterol 1998;12:435-42
- El-Serag HB, Talley NJ. Systemic review: the prevalence and clinical course of functional dyspepsia. Aliment Pharmacol Ther 2004;19:643-54
- Gerson LB, Triadafilopoulos G. A prospective study of oesophageal 24-h ambulatory pH monitoring in patients with functional dyspepsia. Dig Liver Dis 2005;37:87-91
- Lee KJ, Demarchi B, Demedts I, et al. A pilot study on duodenal acid exposure and its relationship to symptoms in functional dyspepsia with prominent nausea. Am J Gastroenterol 2004;99:1765-73
- Moayyedi P, Soo S, Deeks J, et al. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006:CD001960
- Raghunath AS, Hungin AP, Cornford CS, Featherstone V. Use of proton pump inhibitors: an exploration of the attitudes, knowledge and perceptions of general practitioners. Digestion 2005;72:212-8
- Jalving M, Koornstra JJ, Wesseling J, et al. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Aliment Pharmacol Ther 2006;24:1341-8
- Salgueiro E, Rubio T, Hidalgo A, Manso G. Safety profile of proton pump inhibitors according to the spontaneous reports of suspected adverse reactions. Int J Clin Pharmacol Ther 2006;44:548-56
- Diav-Citrin O, Arnon J, Shechtman S, et al. The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study. Aliment Pharmacol Ther 2005;21:269-75
- Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008;128:35-44
- Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006;296:2947-53
- Mallow S, Rebuck JA, Osler T, et al. Do proton pump inhibitors increase the incidence of nosocomial pneumonia and related infectious complications when compared with histamine-2 receptor antagonists in critically ill trauma patients? Curr Surg 2004;61:452-8
- Akhtar AJ, Shaheen M. Increasing incidence of clostridium difficile-associated diarrhea in African-American and Hispanic patients: association with the use of proton pump inhibitor therapy. J Natl Med Assoc 2007;99:500-4
- Glatzel D, Abdel-Qader M, Gatz G, Pfaffenberger B. Pantoprazole 40 mg is as effective as esomeprazole 40 mg to relieve symptoms of gastroesophageal reflux disease after 4 weeks of treatment and superior regarding the prevention of symptomatic relapse. Digestion 2007;75(Suppl 1):69-78
- Piccoli F, Ory G, Hadengue A, et al. Effect of intravenous esomeprazole 40 mg and pantoprazole 40 mg on intragastric pH in healthy subjects. A prospective, open, randomised, two-way cross-over comparative study. Arzneimittelforschung 2007;57:654-8
- Kirchhoff P, Andersson K, Socrates T, et al. Characteristics of the K+-competitive H+,K+-ATPase inhibitor AZD0865 in isolated rat gastric glands. Am J Physiol Gastrointest Liver Physiol 2006;291:G838-43